Scarica l'app Stockscreener
7.11
1.28%
0.09
Dopo l'orario di chiusura:
7.11
Precedente Chiudi:
$7.02
Aprire:
$7.06
Volume 24 ore:
546.68K
Relative Volume:
0.54
Capitalizzazione di mercato:
$473.76M
Reddito:
$80.00M
Utile/perdita netta:
$-76.12M
Rapporto P/E:
-6.2015
EPS:
-1.1465
Flusso di cassa netto:
$-63.88M
1 W Prestazione:
-0.56%
1M Prestazione:
-9.20%
6M Prestazione:
-7.06%
1 anno Prestazione:
+32.90%
Intervallo 1D:
$7.00
$7.195
Intervallo di 1 settimana:
$6.85
$7.63
Portata 52W:
$4.775
$15.74
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Nome
Fulcrum Therapeutics Inc
Settore
Industria
Telefono
617-651-8851
Indirizzo
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
7.11 | 467.77M | 80.00M | -76.12M | -63.88M | -1.1465 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-12 | Iniziato | JP Morgan | Overweight |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-07-29 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-09-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | Downgrade | Stifel | Buy → Hold |
| 2024-09-09 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-05-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-09-25 | Iniziato | Goldman | Neutral |
| 2023-08-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | Aggiornamento | Stifel | Hold → Buy |
| 2023-05-04 | Downgrade | Goldman | Buy → Neutral |
| 2023-03-10 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | Downgrade | Stifel | Buy → Hold |
| 2023-02-28 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-11-15 | Iniziato | Goldman | Buy |
| 2022-03-08 | Iniziato | Oppenheimer | Outperform |
| 2022-03-03 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-08-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-22 | Iniziato | Credit Suisse | Outperform |
| 2021-03-02 | Iniziato | Stifel | Buy |
| 2020-10-16 | Iniziato | Piper Sandler | Overweight |
| 2020-08-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-08-12 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-12 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2019-10-03 | Iniziato | H.C. Wainwright | Buy |
| 2019-08-12 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Fulcrum Therapeutics Inc Borsa (FULC) Ultime notizie
Fulcrum Therapeutics shares climb after Q1 earnings outperform expectations - MSN
Fulcrum Therapeutics (NASDAQ:FULC) Rating Increased to Sell at Wall Street Zen - MarketBeat
Fulcrum Therapeutics (FULC) director receives 64,000 stock options at $8.08 strike price - Stock Titan
Fulcrum Therapeutics (NASDAQ: FULC) director files Form 3 with no shares owned - Stock Titan
Executive pay and auditor vote at Fulcrum Therapeutics (NASDAQ: FULC) - Stock Titan
HC Wainwright Issues Optimistic Estimate for FULC Earnings - MarketBeat
Facioscapulohumeral Muscular Dystrophy Market: Pharma Pipeline Fuels Rapid Expansion – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics - Barchart.com
Facioscapulohumeral Muscular Dystrophy Market: Pharma - openPR.com
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
FULC Should I Buy - Intellectia AI
Fulcrum Therapeutics Shares Surge After Beating Q1 Earnings Estimates - HarianBasis.co
H.C. Wainwright Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Maintains Target Price $25 - Moomoo
A Quick Look at Today's Ratings for Fulcrum Therapeutics(FULC.US), With a Forecast Between $10 to $25 - Moomoo
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q1 2026 Earnings Call Transcript - Insider Monkey
Fulcrum Therapeutics Inc (FULC) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Rising Expenses - GuruFocus
Fulcrum Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap DownTime to Sell? - MarketBeat
Fulcrum Therapeutics Q1 Earnings Call Highlights - Yahoo Finance
Fulcrum Therapeutics, Inc. Q1 2026 Financial Results and Forward-Looking Statements Overview - Minichart
Fulcrum Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Fulcrum Therapeutics Reports Positive Pociredir Data in Sickle Cell Disease, Strong Cash Position Through 2029 - Minichart
Value Trap or Opportunity? Fulcrum Therapeutics (FULC) Q1 2026 E - GuruFocus
Fulcrum Therapeutics (FULC) CFO Alan Musso to Retire This Year - GuruFocus
Fulcrum (FULC) Reports Financial Update and Clinical Progress - GuruFocus
Earnings call transcript: Fulcrum Therapeutics reports Q1 2026 earnings beat - Investing.com
Fulcrum Therapeutics Q1 2026 Earnings Call: Complete Transcript - Benzinga
Fulcrum Therapeutics, Inc. Announces Retirement of Alan Musso as Chief Financial Officer - marketscreener.com
Fulcrum Therapeutics (NASDAQ:FULC) Beats Q1 Estimates as Pociredir Data Fuels Optimism - ChartMill
Fulcrum Therapeutics adds former Oxbryta developer to board By Investing.com - Investing.com South Africa
Fulcrum Therapeutics adds former Oxbryta developer to board - Investing.com
Fulcrum Therapeutics Highlights Q1 Results and Sickle Cell Progress - TipRanks
FULCRUM THERAPEUTICS ($FULC) Releases Q1 2026 Earnings - Quiver Quantitative
Fulcrum Therapeutics stock rises nearly 3% on first quarter earnings beat By Investing.com - Investing.com South Africa
Fulcrum Therapeutics stock rises nearly 3% on first quarter earnings beat - Investing.com India
Fulcrum Therapeutics 10-Q: Revenue $0, EPS $(0.25) for Q1 2026 - TradingView
Pociredir data and long cash runway at Fulcrum Therapeutics (NASDAQ: FULC) - Stock Titan
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026 - The Manila Times
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors - The Manila Times
Fulcrum Therapeutics Inc. (FULC) Tops Q1 EPS by 5c - StreetInsider
[8-K] Fulcrum Therapeutics, Inc. Reports Material Event - Stock Titan
Fulcrum Therapeutics Appoints Dr. Josh Lehrer to Board of Directors - Quiver Quantitative
BRIEF-Fulcrum Therapeutics Q1 Basic EPS USD -0.25 - TradingView
After sickle cell data, Fulcrum plans late-2026 study - Stock Titan
Press Release: Fulcrum Therapeutics Appoints Josh Lehrer to Its Board of Directors - Moomoo
FULC.O Technical Analysis & Stock Price Forecast - Intellectia AI
Fulcrum Therapeutics (FULC) Expected to Announce Quarterly Earnings on Monday - MarketBeat
FULC.O PE Ratio & Valuation, Is FULC.O Overvalued - Intellectia AI
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 4.9%Time to Sell? - MarketBeat
Is Fulcrum Therapeutics (FULC) stock overpriced relative to performance (Pulls Back) 2026-04-20Sector Rotation - Xã Châu Thành
Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET - The Manila Times
Fulcrum schedules April 27 webcast on first-quarter results and updates - Stock Titan
Fulcrum Therapeutics Inc Azioni (FULC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.77%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):